|
1) Zimmet P, Magliano D, Matsuzawa Y, et al. The metabolic syndrome: A global public health problem and a new definition. J ATheroscler Thromb. 2005; 12: 295-300
|
|
|
|
2) Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004; 24: 29-33
|
|
|
|
|
3) 吉田 博. メタボリックシンドロームの概念. 機能性食品と薬理栄養. 2007; 4: 71-7
|
|
|
|
|
|
4) 齋藤 康. 肥満が主体のメタボリックシンドロームの薬物治療. 抗肥満薬. 日本臨牀. 2006; 64 Suppl 9: 655-9
|
|
|
|
|
|
5) Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenoic drive and peripheral lipogenesis. J Clin Invest. 2003; 112: 423-31
|
|
|
|
|
|
6) Kirkham TC, Williams CM. Endocannabinoid receptor antagonists: potential for obesity treatment. Treat Endocrinol. 2004; 3: 345-60
|
|
|
|
|
|
7) Osei-Hyiaman D, Harvey-White J, Batkai S, et al. The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes. 2006; 30: 533-8
|
|
|
|
|
|
8) Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor anagonist SR 141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa Rats and in cultured adipocyte cells. Mol Pharmacol. 2003; 63: 908-14
|
|
|
|
|
|
9) Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005; 115: 1298-305
|
|
|
|
|
|
10) Karsak M, Gaffal E, Date R, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science. 2007; 316: 1494-7
|
|
|
|
|
|
11) Bifulco M, Grimaldi C, Gazzerro P, et al. Rimonabant: Just an antiobestic drug？ Current evidence on its pleiotropic effects. Mol Pharmacol. 2007; 71: 1445-56
|
|
|
|
|
|
12) Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007; 369: 71-7
|
|
|
|
|
|
13) Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365: 1389-97
|
|
|
|
|
|
14) Despres J-P, Golay A, Sjostrom L; for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353: 2121-34
|
|
|
|
|
|
15) Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006; 295: 761-75
|
|
|
|
|
|
16) Scheen AJ, Finer N, Hollander P, et al; for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006; 368: 1660-72
|
|
|
|
|
|
17) Yoshida H, Hirowatari Y, Kurosawa H, et al. Implications of decreased serum adiponectin for type IIb hyperlipidaemia and increased cholesterol levels of very-low-density lipoprotein in type II diabetic patients. Clin Sci. 2005; 109: 297-302
|
|
|
|
|
|
18) Cahill K, Ussher M. Caanabinoid type 1 receptor antagonist (rimonabant) for smoking cessation. Cochran Database Syst Rev. 2007; July 18: CD005353
|
|
|
|
|